I did listen to this webinar. There were three presenters,
Endpoints has just put up the questions asked, and answers, this was not on the webinar, and is interesting reading.
I will put a link here. The last point , i.e. , the relative ease , for running trials in OV therapy, with an IV dose needing .
minutes, compared to IV infusion in a clinic for four hours, is worth noting.
A brief summary:
Paul Peter Tak, Candel therapeutics, works with HSV virus, trial in Prostate cancer, IT , no IV. Study started 2011, completing Dec 2024 . ( talk about needing patience) also study into glioblastoma.
Howard Kaufman , CEO Ankara, also intratumoral only. Only “ clinical” work has been in dogs! Humans” coming soon”
Adina Pelusio . With KaliVir.. also using vaccinia, working on IV use. Again only clinical work in dogs. An unlisted company. She was impressive.
issuses discussed were , needing good study design, targeting the right tumour, RECIST esp tumour size, with regard to tumour pseudo progression.
All this prompted me to have a good look at T-VEC. AMGEN is a huge company, T-VEC is a good earner, but by no means their most important. Notably, they have no ongoing research into OV’s. I guess they just buy out what they want.
All up, I think if there is another update webinar in this field, I believe that YF will be invited . OV’s are a tough field, these speakers have been in it for decades. I’m feeling very good about CF 33 , etc
https://endpts.com/oncolytic-virus-experts-discuss-biggest-lessons-from-past-failures/
- Forums
- ASX - By Stock
- IMU
- Ann: Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study
Ann: Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study, page-102
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.3¢ |
Change
-0.001(1.85%) |
Mkt cap ! $389.5M |
Open | High | Low | Value | Volume |
5.5¢ | 5.6¢ | 5.3¢ | $615.0K | 11.39M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 2977440 | 5.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 283236 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 2977440 | 0.053 |
25 | 3109336 | 0.052 |
24 | 2300422 | 0.051 |
66 | 4218756 | 0.050 |
23 | 3155527 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 283236 | 4 |
0.055 | 1134647 | 7 |
0.056 | 1642592 | 7 |
0.057 | 1624353 | 11 |
0.058 | 230000 | 3 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online